Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’

Código QR

Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicolas Jacquelot, Laurence Zitvogel, Alexander M. Eggermont
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/4a227f9f66da4e72a04ff9db53f1c681
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
por: Lieve Brochez, et al.
Publicado: (2018)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: N. Jacquelot, et al.
Publicado: (2017)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Clemens Hinterleitner, et al.
Publicado: (2021)

The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
por: Gui-Zhen Wang, et al.
Publicado: (2019)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kensuke Kojima, et al.
Publicado: (2021)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: A. Flaus, et al.
Publicado: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Sarah J. Dart, et al.
Publicado: (2021)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
por: Douglas B. Johnson, et al.
Publicado: (2016)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021)

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
por: Wantong Song, et al.
Publicado: (2018)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Marisa Schmitt, et al.
Publicado: (2021)

miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma
por: Mai-Huong Thi Nguyen, et al.
Publicado: (2021)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
por: Jean-Marie Michot, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021)

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
por: Noha M. Hammad, et al.
Publicado: (2021)

Mutation load estimation model as a predictor of the response to cancer immunotherapy
por: Guan-Yi Lyu, et al.
Publicado: (2018)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)

PD-L1 expression in angiomatoid fibrous histiocytoma
por: Joshua Byers, et al.
Publicado: (2021)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Jing Zhou, et al.
Publicado: (2022)

High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis
por: Yoonhyuk Jang, et al.
Publicado: (2018)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Thomas F Gajewski, et al.
Publicado: (2021)

LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
por: E. V. Abakushina, et al.
Publicado: (2015)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li SY, et al.
Publicado: (2013)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Anna Pawłowska, et al.
Publicado: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
por: Vicky Smith, et al.
Publicado: (2021)

Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Antoni Ribas, et al.
Publicado: (2021)

Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse
por: Roxana Khazen, et al.
Publicado: (2016)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021)

Dermoscopic Predictors of Tumor Thickness in Cutaneous Melanoma: A Retrospective Analysis of 245 Melanomas
por: Enrique Rodríguez-Lomba, et al.
Publicado: (2021)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Elena Galvani, et al.
Publicado: (2020)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Christine Bekos, et al.
Publicado: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
por: Yoshihisa Shimada, et al.
Publicado: (2021)